A state court in Washington is slated next week to hear the 1st trial in a group of civil lawsuits filed by the families of patients who died on the operating table minutes after injection with the Norian XR bone cement then made by now-Johnson & Johnson (NYSE:JNJ) subsidiary Synthes. At least 5 patients died during […]
Royal DSM
Biomet’s prelims show improvement in U.S. ortho market | Wall Street Beat
Things are looking up for the U.S. orthopedics market, as preliminary results for Biomet Inc.‘s 2nd quarter suggest strong growth in domestic knee and hip devices sales.
Privately held Biomet, considered something of a bellwether for the U.S. orthopedics market, touted 6% year-over-year growth in knees and 8% in hips.
Smokers in China tip the scale in med-tech’s favor | Wall Street Beat
The Chinese medical device market may triple by 2018, partially due to high rates of tobacco consumption and a rapidly growing economy, according to a market report.
Kensey Nash shareholders sue to block Royal DSM merger | Legal News
MassDevice.com +3 | The top 3 med-tech stories for May 3, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Kensey Nash agrees to $360M buyout by Royal DSM
Kensey Nash (NSDQ:KNSY) agreed to a $38.50-per-share cash buyout offer from Royal DSM worth about $360 million, a 33% premium over KNSY’s $29.01 closing price yesterday.
KNSY shares soared 32.2% in pre-market trading on the news, reaching $38.35 – 25.7% above its 52-week high of $30.50 per share, even as the company revealed a 3rd-quarter swing from red ink to black.
